Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage

Short summary

Thrombolytic therapy for pulmonary embolism (PE) significantly reduces all-cause mortality (2.17% vs 3.89%) and recurrent PE (1.17% vs 3.04%), but substantially increases major bleeding (9.24% vs 3.42%) and intracranial hemorrhage (ICH) (1.46% vs 0.19%), according to a meta-analysis of 16 trials (2115 patients).

AI-generated from the title and abstract; the full text is not read.